B lymphocyte stimulator (BLyS) isoforms in systemic lupus erythematosus: disease activity correlates better with blood leukocyte BLyS mRNA levels than with plasma BLyS protein levels

[1]  A. Steinberg,et al.  Quantitation of IgM- and IgG-secreting B cells in the peripheral blood of patients with systemic lupus erythematosus. , 2010, Arthritis and rheumatism.

[2]  D. Hilbert,et al.  Circulating levels of B lymphocyte stimulator in patients with rheumatoid arthritis following rituximab treatment: relationships with B cell depletion, circulating antibodies, and clinical relapse. , 2006, Arthritis and rheumatism.

[3]  M. Pelletier,et al.  Expression and occupancy of BAFF-R on B cells in systemic lupus erythematosus. , 2005, Arthritis and rheumatism.

[4]  C. Putterman,et al.  BAFF overexpression and accelerated glomerular disease in mice with an incomplete genetic predisposition to systemic lupus erythematosus. , 2005, Arthritis and rheumatism.

[5]  V. Roschke,et al.  Proinflammatory mediators elicit secretion of the intracellular B-lymphocyte stimulator pool (BLyS) that is stored in activated neutrophils: implications for inflammatory diseases. , 2005, Blood.

[6]  Ehrenstein,et al.  Serological changes following B cell depletion therapy in Systemic Lupus Erythematosus: Relationship with BLyS , 2004 .

[7]  K. E. Schwartz,et al.  Effects of prasterone on disease activity and symptoms in women with active systemic lupus erythematosus. , 2004, Arthritis and rheumatism.

[8]  T. Phan,et al.  Excess BAFF rescues self-reactive B cells from peripheral deletion and allows them to enter forbidden follicular and marginal zone niches. , 2004, Immunity.

[9]  J. Cyster,et al.  Reduced competitiveness of autoantigen-engaged B cells due to increased dependence on BAFF. , 2004, Immunity.

[10]  M. Scott,et al.  Cutting Edge: BAFF Regulates CD21/35 and CD23 Expression Independent of Its B Cell Survival Function , 2004, The Journal of Immunology.

[11]  V. Roschke,et al.  B lymphocyte stimulator overexpression in patients with systemic lupus erythematosus: longitudinal observations. , 2003, Arthritis and rheumatism.

[12]  C. Ware,et al.  ΔBAFF, an Alternate Splice Isoform That Regulates Receptor Binding and Biopresentation of the B Cell Survival Cytokine, BAFF* , 2003, Journal of Biological Chemistry.

[13]  S. Tangye,et al.  BAFF selectively enhances the survival of plasmablasts generated from human memory B cells. , 2003, The Journal of clinical investigation.

[14]  I. Maclennan,et al.  NF-κB1 p50 Is Required for BLyS Attenuation of Apoptosis but Dispensable for Processing of NF-κB2 p100 to p52 in Quiescent Mature B Cells1 , 2003, The Journal of Immunology.

[15]  Karin Reiter,et al.  Correlation between circulating CD27high plasma cells and disease activity in patients with systemic lupus erythematosus. , 2003, Arthritis and rheumatism.

[16]  V. Roschke,et al.  Local production of B lymphocyte stimulator protein and APRIL in arthritic joints of patients with inflammatory arthritis. , 2003, Arthritis and rheumatism.

[17]  B. Nardelli,et al.  G-CSF–stimulated Neutrophils Are a Prominent Source of Functional BLyS , 2003, The Journal of experimental medicine.

[18]  D. Isenberg,et al.  An open study of B lymphocyte depletion in systemic lupus erythematosus. , 2002, Arthritis and rheumatism.

[19]  D. Seshasayee,et al.  BAFF/BLyS receptor 3 binds the B cell survival factor BAFF ligand through a discrete surface loop and promotes processing of NF-kappaB2. , 2002, Immunity.

[20]  J. Kearney,et al.  Blood dendritic cells interact with splenic marginal zone B cells to initiate T-independent immune responses. , 2002, Immunity.

[21]  B. Nardelli,et al.  DCs induce CD40-independent immunoglobulin class switching through BLyS and APRIL , 2002, Nature Immunology.

[22]  D. Hilbert,et al.  Cutting Edge: BLyS Enables Survival of Transitional and Mature B Cells Through Distinct Mediators1 , 2002, The Journal of Immunology.

[23]  D. Hilbert,et al.  Competition for BLyS-mediated signaling through Bcmd/BR3 regulates peripheral B lymphocyte numbers , 2001, Current Biology.

[24]  M. Scott,et al.  An Essential Role for BAFF in the Normal Development of B Cells Through a BCMA-Independent Pathway , 2001, Science.

[25]  S. Dillon,et al.  TACI-Ig neutralizes molecules critical for B cell development and autoimmune disease. impaired B cell maturation in mice lacking BLyS. , 2001, Immunity.

[26]  V. Roschke,et al.  Elevated serum B lymphocyte stimulator levels in patients with systemic immune-based rheumatic diseases. , 2001, Arthritis and rheumatism.

[27]  G. Alarcón,et al.  Cutting Edge: A Role for B Lymphocyte Stimulator in Systemic Lupus Erythematosus1 , 2001, The Journal of Immunology.

[28]  J. Tschopp,et al.  Baff Mediates Survival of Peripheral Immature B Lymphocytes , 2000, The Journal of experimental medicine.

[29]  P. Lipsky,et al.  Disturbed Peripheral B Lymphocyte Homeostasis in Systemic Lupus Erythematosus1 , 2000, The Journal of Immunology.

[30]  M. Tourigny,et al.  Attenuation of Apoptosis Underlies B Lymphocyte Stimulator Enhancement of Humoral Immune Response , 2000, The Journal of experimental medicine.

[31]  J. Tschopp,et al.  Baff Binds to the Tumor Necrosis Factor Receptor–Like Molecule B Cell Maturation Antigen and Is Important for Maintaining the Peripheral B Cell Population , 2000, The Journal of experimental medicine.

[32]  Don Foster,et al.  TACI and BCMA are receptors for a TNF homologue implicated in B-cell autoimmune disease , 2000, Nature.

[33]  D. Lacey,et al.  Severe B cell hyperplasia and autoimmune disease in TALL-1 transgenic mice. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[34]  J. Tschopp,et al.  Mice Transgenic for Baff Develop Lymphocytic Disorders along with Autoimmune Manifestations , 1999, The Journal of experimental medicine.

[35]  Amy S Orr,et al.  BLyS: member of the tumor necrosis factor family and B lymphocyte stimulator. , 1999, Science.

[36]  J. Tschopp,et al.  BAFF, a Novel Ligand of the Tumor Necrosis Factor Family, Stimulates B Cell Growth , 1999, The Journal of experimental medicine.

[37]  Leslie J. Crofford,et al.  Primer on the Rheumatic Diseases , 1999 .

[38]  D. Sackett,et al.  Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE. , 1992, Arthritis and rheumatism.

[39]  B. Doft,et al.  Increased spontaneous activity of antibody-forming cells in the peripheral blood of patients with active SLE. , 1977, Arthritis and rheumatism.

[40]  V. Roschke,et al.  Proinflammatory mediators elicit the secretion of the intracellular B- lymphocyte stimulator (BLyS) pool that is stored in activated neutrophils: implications for inflammatory diseases. Short Title: Inducible BLyS secretion by activated neutrophils , 2004 .

[41]  P. Moore,et al.  Synthesis and release of B-lymphocyte stimulator from myeloid cells. , 2001, Blood.

[42]  P. Lipsky,et al.  Circulating and pokeweed mitogen-induced immunoglobulin-secreting cells in systemic lupus erythematosus. , 1979, Clinical and experimental immunology.